Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | IDE | P14735 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.59 |
| ▸ | HLCS | P50747 | 2/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171661 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL565479 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16913029 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2153169 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3143245 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL25417015 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1270494 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18257230 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22975316 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL565248 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107515-A1 | INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME | DIASOME PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | claimed |
| CN-119403786-A | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes | 德罗普尼尔生物有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2024-05-02 | — | — | US | claimed |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | claimed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | claimed |
| US-20220110870-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2022-04-14 | — | — | US | claimed |
| EP-3952904-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| EP-2501702-B1 | METHOD FOR PREPARING N-SUCCINIMIDYL N-BIOTINYL-6-AMINOCAPROATE | SANOFI SA (FR) | 2014-08-06 | — | — | EP | claimed |
| EP-2501702-A1 | METHOD FOR PREPARING N-SUCCINIMIDYL N-BIOTINYL-6-AMINOCAPROATE | SANOFI (FR) | 2012-09-26 | — | — | EP | claimed |
| WO-2011061449-A1 | METHOD FOR PREPARING N-SUCCINIMIDYL N-BIOTINYL-6-AMINOCAPROATE | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | WO | claimed |
| EP-1385998-A1 | BIOMOLECULE CHARACTERIZATION USING MASS SPECTROMETRY AND AFFINITY TAGS | Ciphergen Biosystems, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030077616-A1 | Biomolecule characterization using mass spectrometry and affinity tags | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-04-24 | — | — | US | claimed |
| WO-2002086168-A1 | BIOMOLECULE CHARACTERIZATION USING MASS SPECTROMETRY AND AFFINITY TAGS | CIPHERGEN BIOSYSTEMS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| EP-0379949-B1 | Method for the determination of HIV antibodies | BOEHRINGER MANNHEIM GMBH (DE) | 1995-03-29 | — | — | EP | claimed |
| US-5001049-A | Method for determination of HIV specific antibodies | BOEHRINGER MANNHEIM GMBH (DE) | 1991-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | TDP1 4738/4885MEN1 1515/4885ABL1 2221/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | TDP1 2734/4885MEN1 2813/4885ABL1 3892/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | TDP1 4755/4885MEN1 2415/4885ABL1 4626/4885 |
| US-20220110870-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885MEN1 1400/4885ABL1 3769/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | TDP1 4833/4885MEN1 2073/4885ABL1 4576/4885 |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | TDP1 4800/4885MEN1 561/4885ABL1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.